Technologies

Technical Summary

The glutathione and glutathione disulfide compositions used in this technology inhibit the production of infectious virus particles likely by interrupting the protease cleavage of viral hemagglutinin after the viral particles are released. By preventing extracellular activation of the virus, these compositions do not interfere with intracellular processes, allowing apoptosis of infected cells to proceed normally. Also, because the compositions work extracellularly, they can be delivered directly without the use of injections. Finally, this technology, by acting directly on the virus rather than conferring immunity to specific strains, may act to prevent and treat a broader range of strains than traditional immunization techniques.
In the U.S. alone, more than 200,000 people are hospitalized for flu-related complications, and about 36,000 people die from flu-related causes.